OGEN - Oragenics secures $20M capital raise

Oragenics (OGEN) announces that it has raised about $20M from the sale of its shares through an agreement with A.G.P./Alliance Global Partners for an "at-the-market" facility.The company also received about $1.9M from the exercise of common stock warrants.Oragenics has given a notice for the redemption of all outstanding shares of its series C, non-convertible, preferred stock to the holder. The redemption payment date will be March 15, 2021.The company said it expects to use the raised capital to fund development of its SARS CoV-2 vaccine, Terra CoV-2, and to advance its lantibiotics program.Oragenics shares down nearly 3% premarket.

For further details see:

Oragenics secures $20M capital raise